ClinicalTrials.gg
CompletedNCT04639804Updated Nov 23, 2020

Pharmacokinetic Interaction Between Tegoprazan and NSAIDs After Multiple Oral Dosing in Healthy Male Volunteers

A Phase 1 interventional study of Tegoprazan and Naproxen in Healthy, sponsored by HK inno.N Corporation. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-11-23.

Sponsored by HK inno.N Corporation · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jun 2020, registered Nov 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
Male
01

Study summary

This study aims to evaluate the pharmacokinetic (PK) interaction between tegoprazan and non-steroidal anti-inflammatory drugs (NSAIDs) after given each alone and in their combination in healthy male adults.

Read the detailed description

A randomized, open-label, multiple-dose, 6-sequence-arm, 3-period cross-over study

02

Conditions studied

  • Healthy

Keywords

  • drug-drug interaction
  • pharmacokinetic
03

In context

Lead sponsor

HK inno.N Corporation is the lead sponsor of 104 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult aged ≥ 19 and \< 55 year-old at screening
  • (BMI) ≥ 19.0 kg/m2 and \< 27.0 kg/m2 with a body weight ≥ 55 kg at screening.

Exclusion criteria

Exclusion Criteria:

  • History or evidence of disease
  • History of GI disease or surgery that may affect the absorption of a drug
  • Laboratory test result which falls into the following values( or AST > 2 × (ULN))
  • History of regular alcohol consumption exceeding 210 g/week within 6 months
  • Daily use of ≥ 20 cigarettes within 6 months
  • Has taken any agent within 6 months prior to the first dose of IMP
  • Subjects who are considered ineligible to participate in this study at the discretion of the investigator.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    Tegoprazan 50 mg

    Multiple doses of tegoprazan alone once daily (QD) for 7 days

    Drug: Tegoprazan

  • Active comparator
    NSAIDs

    Multiple doses of NSAIDs alone twice daily (BID) for 7 days

    Drug: Naproxen · Drug: Aceclofenac · Drug: Celecoxib

  • Active comparator
    Tegoprazan 50 mg + NSAIDs

    Multiple doses of tegoprazan QD in combination with NSAIDs BID for 7 days

    Drug: Tegoprazan · Drug: Naproxen · Drug: Aceclofenac · Drug: Celecoxib

Interventions

  • Tegoprazan 50 mg tablet

    Also known as: K-CAB

  • Naproxen 500 mg tablet

    Also known as: Naxen-F

  • Aceclofenac 100 mg tablet

    Also known as: Airtal

  • Celecoxib 200 mg capsule

    Also known as: Celebrex 200 mg

06

What researchers measure

Primary outcomes

  1. AUCτ of tegoprazan and NSAIDs

    Area under the plasma concentration-time curve during a steady-state dosing interval (τ) of tegoprazan and NSAIDs

    Time frame: pre-dose (0 hour) on Day1, Day5, Day6 and pre-dose up to 24 hours post-dose on Day7

  2. Css,max of tegoprazan and NSAIDs

    Maximum Plasma Concentration at Steady State of tegoprazan and NSAIDs

    Time frame: pre-dose (0 hour) on Day1, Day5, Day6 and pre-dose up to 24 hours post-dose on Day7

07

Study locations

1 site
  • Chonbuk National University Hospital
    Jeonju, Korea, Republic of
08

References and documents

Publications

  • Moon SJ, Shin N, Kang M, Kim B, Kim MG. Pharmacokinetic Interactions Between Tegoprazan and Naproxen, Aceclofenac, and Celecoxib in Healthy Korean Male Subjects. Clin Ther. 2022 Jul;44(7):930-944.e1. doi: 10.1016/j.clinthera.2022.06.002. Epub 2022 Jul 1. PubMed 35787943 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2020 to primary completion in Jul 2020, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2020
First posted
Nov 23, 2020
StartActual
Jun 6, 2020
Primary completionActual
Jul 26, 2020
CompletionActual
Jul 29, 2020
Last update
Nov 23, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 23, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04639804
Responsible party
Sponsor
First posted
Nov 23, 2020
Start date
Jun 6, 2020
Primary completion
Jul 26, 2020
Completion
Jul 29, 2020
Last update
Nov 23, 2020

Study contacts

Min-Gul Kim, MD, PhD
principal investigator · Chonbuk university hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tegoprazan · Naproxen · Aceclofenac · Celecoxib

Start the discussion